Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Placebo-controlled, Double-blind, 26 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesias

NCT02153632 is registered in ClinicalTrials.gov with Adamas Pharmaceuticals, Inc. as lead sponsor.

NCT NCT02153632
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02153632 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Placebo-controlled, Double-blind, 26 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesias
Lead sponsor
Adamas Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Terminated
Start date
July 30, 2014
Completion date
May 20, 2016
Enrollment
135 (actual)
Sites
56

Conditions

As the registry lists them; a condition with its own page is linked.

levodopa induced dyskinesia (lid), parkinson's disease